Hemostemix ACP-01: Ischemic Disease Research & Case Discussions
In this webinar, Hemostemix presents an educational update on ACP-01, an investigational, autologous cell therapy, with research context across ischemia and case discussions (e.g., single-case overviews) to support clinician and patient education. We review the science within regenerative medicine, current study directions, and considerations for responsible communication and patient care across ischemic diseases affecting the vascular system, including peripheral arterial disease (PAD), limb ischemia, angina and ischemic cardiomyopathy, cardiomyopathy and cardiomyopathy treatment, congestive heart failure, hardening of the arteries, dementia (context for dementia treatment), and approaches to vascular disease treatment. This webinar also includes two single-case discussions presented in an educational, investigational context: (1) Roger B., whose clinicians reported changes in left-ventricular ejection fraction over time following an ACP-01 procedure, and (2) Howie Lindeman, who described returning to demanding professional activities shortly after his procedure. These are individual experiences shared for education within ongoing research. ACP-01 is investigational and not FDA-approved; outcomes vary. This content is not medical advice. 🔗 Learn more at www.hemostemix.com 📞 Call us: (905) 580-4170 💬 Share this to raise awareness & reach those in need. 🔔Be sure to subscribe and tap the notification bell so you don't miss any exciting news and updates! 🧬Connect with Hemostemix: 💼LinkedIn: / 3212019 🗣️Facebook: https://www.facebook.com/profile.php?... 📸Instagram: / hemostemix.inc 🌐Website: https://hemostemix.com/ ⚠️Important: ACP-01 is investigational and not approved by the U.S. FDA. This video is educational only, not medical advice and not a promotion of an unapproved product. Talk to a qualified clinician about your care. 📍Florida notice: This Notice Must Be Provided To You Under Florida Law. This physician performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy. Chapters 00:00 Introduction to Hemostemics and ACP01 05:44 Patient Stories and Impact of ACP01 10:12 Regulatory Environment and Opportunities in Florida 11:42 Clinical Evidence and Treatment Areas 15:02 How ACP01 Works: The Process 23:38 Future of Hemostemics and Patient Care 27:46 Regulatory Compliance and Clinical Trials 31:48 Reframing Healthcare Standards and Future Directions
